MX365688B - Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino. - Google Patents

Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.

Info

Publication number
MX365688B
MX365688B MX2015002325A MX2015002325A MX365688B MX 365688 B MX365688 B MX 365688B MX 2015002325 A MX2015002325 A MX 2015002325A MX 2015002325 A MX2015002325 A MX 2015002325A MX 365688 B MX365688 B MX 365688B
Authority
MX
Mexico
Prior art keywords
oxaliplatin
bladder
treatment
methods
drug delivery
Prior art date
Application number
MX2015002325A
Other languages
English (en)
Other versions
MX2015002325A (es
Inventor
Giesing Dennis
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of MX2015002325A publication Critical patent/MX2015002325A/es
Publication of MX365688B publication Critical patent/MX365688B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/04—General characteristics of the apparatus implanted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1085—Bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1089—Urethra
    • A61M2210/1096—Male
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/16—Male reproductive, genital organs
    • A61M2210/166—Prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nanotechnology (AREA)

Abstract

Se proporcionan métodos, dispositivos y medicamentos que incluyen oxaliplatino para el uso en el tratamiento del cáncer de vejiga mediante la administración local de oxaliplatino a la vejiga de un paciente para lograr una concentración sostenida de oxaliplatino en la orina en la vejiga suficiente para producir una concentración terapéutica de oxaliplatino en el tejido de la vejiga. El oxaliplatino se puede administrar a la vejiga desde un dispositivo de administración de fármaco intravesical insertado a la vejiga, donde el dispositivo libera continuamente el oxaliplatino a la orina en la vejiga por un período extendido de horas o días.
MX2015002325A 2012-08-31 2013-09-03 Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino. MX365688B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261696027P 2012-08-31 2012-08-31
PCT/US2013/057836 WO2014036555A1 (en) 2012-08-31 2013-09-03 Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin

Publications (2)

Publication Number Publication Date
MX2015002325A MX2015002325A (es) 2015-05-12
MX365688B true MX365688B (es) 2019-06-11

Family

ID=49226511

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002325A MX365688B (es) 2012-08-31 2013-09-03 Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.

Country Status (25)

Country Link
US (2) US10543346B2 (es)
EP (1) EP2890384B1 (es)
JP (1) JP6463266B2 (es)
KR (1) KR102157548B1 (es)
CN (1) CN104640549B (es)
AU (1) AU2013308464B2 (es)
BR (1) BR112015003836A2 (es)
CA (1) CA2882319C (es)
CY (1) CY1124890T1 (es)
DK (1) DK2890384T3 (es)
ES (1) ES2902833T3 (es)
HR (1) HRP20211921T1 (es)
HU (1) HUE056976T2 (es)
IL (1) IL237281B (es)
IN (1) IN2015DN01561A (es)
LT (1) LT2890384T (es)
MX (1) MX365688B (es)
PL (1) PL2890384T3 (es)
PT (1) PT2890384T (es)
RS (1) RS62875B1 (es)
RU (1) RU2657591C2 (es)
SG (1) SG11201501424SA (es)
SI (1) SI2890384T1 (es)
SM (1) SMT202200010T1 (es)
WO (1) WO2014036555A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
CA2882575C (en) 2012-08-31 2020-05-26 Dennis GIESING Drug delivery systems and methods for treatment of prostate
CA2953350C (en) 2014-06-23 2019-11-26 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
IL280619B2 (en) 2015-07-07 2023-10-01 H Lundbeck As Phosphodiesterase 9 inhibitors with an imidazo triazinon or imidazo pyrazinone skeleton for the treatment of peripheral diseases
SG10201913416PA (en) 2016-05-06 2020-03-30 Taris Biomedical Llc Method of treating lower tract urothelial cancer
IL295973A (en) 2016-07-06 2022-10-01 H Lundbeck As pde9 inhibitors for the treatment of peripheral diseases
CA3064004A1 (en) 2017-05-26 2018-11-29 Imara Inc. Methods of making and using pde9 inhibitors
SG10201913998YA (en) 2017-07-25 2020-03-30 Taris Biomedical Llc Methods of treating tumor metastasis
CN111787926A (zh) 2017-11-08 2020-10-16 塔里斯生物医药公司 使用吉西他滨对膀胱癌进行治疗和维持疗法的方法
EP4349403A3 (en) 2018-05-25 2024-06-05 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
JP2021532155A (ja) 2018-08-01 2021-11-25 タリス バイオメディカル エルエルシー トロスピウムを使用した過活動膀胱の治療方法
MA53501A (fr) 2018-08-31 2021-07-07 Imara Inc Inhibiteurs de pde9 pour le traitement de la drépanocytose

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
JP2006506385A (ja) 2002-10-22 2006-02-23 ザ バイオメリックス コーポレーション 治療剤を小嚢内デリバリーするための方法およびシステム
JP2008501650A (ja) * 2004-06-03 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー オキサリプラチンおよびｅｇｆｒ阻害剤を用いた処置
US8361490B2 (en) 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
EP1933810B1 (en) 2005-08-11 2012-10-10 Massachusetts Institute of Technology Intravesical drug delivery device and method
JP5560200B2 (ja) 2007-12-11 2014-07-23 マサチューセッツ インスチテュート オブ テクノロジー 膀胱および他の身体の小嚢又は管腔を治療するための埋め込み型薬物供給デバイス
JP5538359B2 (ja) 2008-04-04 2014-07-02 リペラ ファーマシューティカルズ， インコーポレイテッド リポソームボツリヌス毒素を使用する膀胱機能障害の治療
WO2010009335A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
CN102176931B (zh) 2008-08-09 2015-03-04 麻省理工学院 治疗男性泌尿生殖组织和外周组织的可植入药物递送设备和方法
ES2401008T3 (es) * 2009-06-26 2013-04-16 Taris Biomedical, Inc. Comprimidos farmacéuticos sólidos para dispositivos implantables para la administración de fármacos
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
SI2512581T1 (sl) 2009-12-17 2021-09-30 Taris Biomedical Llc Vsadljiva naprava z intravezikalno sprejemljivostjo
WO2012048114A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
WO2012065044A2 (en) 2010-11-12 2012-05-18 Purdue Research Foundation Treating bladder tumor cells using fibronectin attachment protein as a target
SG191893A1 (en) 2011-01-10 2013-08-30 Taris Biomedical Inc Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
RU2598057C2 (ru) * 2011-02-04 2016-09-20 ТАРИС Биомедикал ЛЛК Имплантируемое устройство для контролируемого высвобождения лекарственного средства с низкой растворимостью
CA2882575C (en) 2012-08-31 2020-05-26 Dennis GIESING Drug delivery systems and methods for treatment of prostate
AU2013318146B2 (en) 2012-09-18 2018-05-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium
SG11201507294WA (en) 2013-03-15 2015-10-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
LT3035991T (lt) 2013-08-19 2020-11-10 Taris Biomedical Llc Daugiablokiai vaistų vartojimo įtaisai

Also Published As

Publication number Publication date
MX2015002325A (es) 2015-05-12
ES2902833T3 (es) 2022-03-30
RS62875B1 (sr) 2022-02-28
HRP20211921T1 (hr) 2022-03-04
US11007355B2 (en) 2021-05-18
SI2890384T1 (sl) 2022-02-28
JP6463266B2 (ja) 2019-01-30
CN104640549B (zh) 2018-09-07
US20150165178A1 (en) 2015-06-18
HUE056976T2 (hu) 2022-04-28
KR20150043507A (ko) 2015-04-22
US10543346B2 (en) 2020-01-28
IL237281B (en) 2019-09-26
PL2890384T3 (pl) 2022-02-14
RU2657591C2 (ru) 2018-06-14
AU2013308464B2 (en) 2018-02-01
EP2890384A1 (en) 2015-07-08
CA2882319C (en) 2020-05-26
AU2013308464A1 (en) 2015-03-05
CY1124890T1 (el) 2023-01-05
PT2890384T (pt) 2022-01-21
CA2882319A1 (en) 2014-03-06
LT2890384T (lt) 2022-01-10
SMT202200010T1 (it) 2022-03-21
JP2015532653A (ja) 2015-11-12
BR112015003836A2 (pt) 2017-07-04
CN104640549A (zh) 2015-05-20
KR102157548B1 (ko) 2020-09-18
DK2890384T3 (da) 2022-01-10
RU2015109296A (ru) 2016-10-20
EP2890384B1 (en) 2021-11-03
WO2014036555A1 (en) 2014-03-06
US20200114133A1 (en) 2020-04-16
IN2015DN01561A (es) 2015-07-03
IL237281A0 (en) 2015-04-30
SG11201501424SA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
MX2020002465A (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros transtornos del tracto urinario inferior.
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
EP4461326A3 (en) Flexible system for delivering an anchor
WO2012002760A3 (ko) 세균유래 마이크로베시클을 이용한 암치료 및 암진단 방법
WO2012037355A3 (en) Photodynamic therapy system, device and associated method of treatment
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2014197632A3 (en) Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
EP2392363A3 (en) Drug coated expandable devices
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
EP3590338A3 (en) Medical treatments based on anamorelin
WO2011133957A3 (en) Devices for delivering neuro-electro-adaptive therapy (neat)
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
EA032959B9 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции
NZ631362A (en) Arry-520 for use in treating cancer in a patient with low aag
WO2011028800A3 (en) Treatment of cognitive dysfunction with gangliosides
Barsotti CMV lung infection, bladder infection and erythematous rash: 3 case reports
WO2011031018A3 (ko) 서방형 방출이 가능한 수용성 약물 전달 시스템

Legal Events

Date Code Title Description
FG Grant or registration